Humunis (Human Chorionic Gonadotropin Hormone 5000 I.U Injection)

HUMUNIS Injection contains Human Chorionic Gonadotropin Hormone. It is a hormone produced by the cells that surround the growing human embryo. These cells eventually form the placenta. Human Chorionic Gonadotropin is detected in the urine from 7-9 days post-fertilisation as the embryo attaches and implants in the womb.
It is important that the corpus luteum keeps producing progesterone because loss of progesterone leads to menstruation, which would prevent an embryo from implanting. HCG is a embryonic hormone which ensures the corpus luteum continues to produce progesterone throughout the first trimester of pregnancy.


HCG is a glycoprotein hormone.

1-2 HUMUNIS Injections to induce ovulation, following treatment with an FSH (Follicle Stimulating Hormone) or HMG (Human Menopausal Gonadotrophins) preparation.

Hypogonadotrophic hypogonadism: 1-2 HUMUNIS Injections 2-3 times weekly.

Prepubertal cryptorchidism not due to anatomical obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9.
Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.
Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.
HCG is an important tumor marker especially (with clinical significance) in Gestational trophoblastic disease.
In the male, hCG injections are used to stimulate the leydig cells to synthesize testosterone. The intratesticular testosterone is necessary for spermatogenesis from the sertoli cells. Typical uses for hCG in men include hypogonadism and fertility treatment.

Chorionic Gonadotropin binds to the Follicle Stimulating Hormone (FSH) receptor which results in ovulation in the absence of sufficient endogenous luteinizing hormone.
In adult and adolescent men with hypogonadotropic hypogonadism, HCG acts like LH and stimulates testosterone production in the Leydig cells and spermatogenesis in the seminiferous tubules. Stimulation of androgen production by HCG causes development of secondary sex characteristics in males. HCG also stimulates the Leydig cells to produce estrogens; increased estrogen levels may produce gynecomastia in some males. Once HCG is initiated, it takes at least 70-80 days for germ cells to reach the spermatozoal stage. Induction of testicular growth and increased sperm volumes may help to restore fertility in these men aftera duration of treatment.